The data indicate that targeting CX3CR1 to induce HRD and sensitize to PARPis could be a potentially viable therapeutic approach, although more research is needed to further optimize the drug treatment regimen in preclinical models and to identify the molecular profile of cancers that are likely to respond to this therapeutic approach. This evidence concerns the gene CX3CR1 and cancer.